ena-STUDY-MCGILL UNIVERSITY-13-03-2019-18:45:04:456-578
Novel Candidate Alleles for Hereditary Breast Cancer Identified in BRCA1/2 Negative Greek Families by exam sequencing
Approximately 10% of breast cancer (BC) cases are hereditary (HBC), with HBC most commonly encountered in the context of hereditary breast and ovarian cancer syndrome (HBOC). Although thousands of loss-of-function (LoF) alleles in over 20 genes have been associated with HBC susceptibility, the genetic etiology of approximately 70% of cases remains unexplained. We focused on one of the least-studied European populations and applied whole exome sequencing (WES) to 52 individuals from 17 Greek HBOC families, in which at least one patient was negative for known HBC risk mutations. Prior to our analysis, we screened for mutations in known cancer genes and identified BARD1:p.Trp91* variant in a cancer-free individual and MEN1:p.Glu260Lys variant in a BC patient. Further, we applied gene and variant-based approaches to prioritize candidate variants. Findings were verified in a collection of Canadian HBOC patients of European ancestry (FBRCAX), in an independent groups of Canadian BC patients and controls, as well as in individuals from The Cancer Genome Atlas (TCGA) and the UK Biobank (UKB). Rare LoF variants were uncovered in MDM1 and NBEAL1 in Greek and Canadian HBOC patients. We also report prioritized missense variants SETBP1:c.4129G>C and C7orf34:c.248C>T. These variants comprise promising candidates whose role in cancer pathogenicity needs to be explored further.
Approximately 10% of breast cancer (BC) cases are hereditary (HBC), with HBC most commonly encountered in the context of hereditary breast and ovarian cancer syndrome (HBOC). Although thousands of loss-of-function (LoF) alleles in over 20 genes have been associated with HBC susceptibility, the genetic etiology of approximately 70% of cases remains unexplained. We focused on one of the least-studied European populations and applied whole exome sequencing (WES) to 52 individuals from 17 Greek HBOC families, in which at least one patient was negative for known HBC risk mutations. Prior to our analysis, we screened for mutations in known cancer genes and identified BARD1:p.Trp91* variant in a cancer-free individual and MEN1:p.Glu260Lys variant in a BC patient. Further, we applied gene and variant-based approaches to prioritize candidate variants. Findings were verified in a collection of Canadian HBOC patients of European ancestry (FBRCAX), in an independent groups of Canadian BC patients and controls, as well as in individuals from The Cancer Genome Atlas (TCGA) and the UK Biobank (UKB). Rare LoF variants were uncovered in MDM1 and NBEAL1 in Greek and Canadian HBOC patients. We also report prioritized missense variants SETBP1:c.4129G>C and C7orf34:c.248C>T. These variants comprise promising candidates whose role in cancer pathogenicity needs to be explored further.